You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Corcept Therapeutics Incorporated (CORT) - free report >>
Sandstorm Gold Ltd (SAND) - free report >>
Y-mAbs Therapeutics, Inc. (YMAB) - free report >>
Image: Shutterstock
New Strong Buy Stocks for April 17th
Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:
Byrna Technologies Inc. (BYRN - Free Report) : This non-lethal defense technology companyhas seen the Zacks Consensus Estimate for its current year earnings increasing 157.1% over the last 60 days.
Byrna Technologies Inc. Price and Consensus
Byrna Technologies Inc. price-consensus-chart | Byrna Technologies Inc. Quote
Y-mAbs Therapeutics, Inc. (YMAB - Free Report) : This commercial-stage biopharmaceutical company has seen the Zacks Consensus Estimate for its current year earnings increasing 42.7% over the last 60 days.
Y-mAbs Therapeutics, Inc. Price and Consensus
Y-mAbs Therapeutics, Inc. price-consensus-chart | Y-mAbs Therapeutics, Inc. Quote
Sandstorm Gold Ltd. (SAND - Free Report) : This gold royalty company has seen the Zacks Consensus Estimate for its current year earnings increasing 16.7% over the last 60 days.
Sandstorm Gold Ltd Price and Consensus
Sandstorm Gold Ltd price-consensus-chart | Sandstorm Gold Ltd Quote
Corcept Therapeutics Incorporated (CORT - Free Report) : This pharmaceutical company has seen the Zacks Consensus Estimate for its current year earnings increasing 27.8% over the last 60 days.
Corcept Therapeutics Incorporated Price and Consensus
Corcept Therapeutics Incorporated price-consensus-chart | Corcept Therapeutics Incorporated Quote
Enveric Biosciences, Inc. (ENVB - Free Report) : This biotechnology company has seen the Zacks Consensus Estimate for its next year earnings increasing 25.6% over the last 60 days.
Enveric Biosciences, Inc. Price and Consensus
Enveric Biosciences, Inc. price-consensus-chart | Enveric Biosciences, Inc. Quote
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.